全文获取类型
收费全文 | 7995篇 |
免费 | 528篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 131篇 |
妇产科学 | 94篇 |
基础医学 | 1066篇 |
口腔科学 | 233篇 |
临床医学 | 840篇 |
内科学 | 1542篇 |
皮肤病学 | 110篇 |
神经病学 | 949篇 |
特种医学 | 585篇 |
外科学 | 1455篇 |
综合类 | 30篇 |
一般理论 | 1篇 |
预防医学 | 231篇 |
眼科学 | 186篇 |
药学 | 459篇 |
中国医学 | 14篇 |
肿瘤学 | 575篇 |
出版年
2023年 | 81篇 |
2022年 | 77篇 |
2021年 | 357篇 |
2020年 | 203篇 |
2019年 | 248篇 |
2018年 | 309篇 |
2017年 | 230篇 |
2016年 | 359篇 |
2015年 | 380篇 |
2014年 | 464篇 |
2013年 | 492篇 |
2012年 | 773篇 |
2011年 | 705篇 |
2010年 | 421篇 |
2009年 | 366篇 |
2008年 | 566篇 |
2007年 | 497篇 |
2006年 | 436篇 |
2005年 | 412篇 |
2004年 | 335篇 |
2003年 | 318篇 |
2002年 | 226篇 |
2001年 | 34篇 |
2000年 | 21篇 |
1999年 | 31篇 |
1998年 | 24篇 |
1997年 | 26篇 |
1996年 | 7篇 |
1995年 | 17篇 |
1994年 | 12篇 |
1993年 | 8篇 |
1992年 | 7篇 |
1991年 | 12篇 |
1989年 | 10篇 |
1988年 | 8篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 5篇 |
1984年 | 7篇 |
1983年 | 7篇 |
1981年 | 5篇 |
1979年 | 4篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 5篇 |
1975年 | 4篇 |
1973年 | 3篇 |
1970年 | 4篇 |
1969年 | 3篇 |
1966年 | 4篇 |
排序方式: 共有8563条查询结果,搜索用时 203 毫秒
1.
Florian Huemer Thomas Melchardt Bettina Jansko Adam Wahida Stefanie Jilg Philipp J. Jost Eckhard Klieser Katja Steiger Teresa Magnes Lisa Pleyer Sigrun Greil‐Ressler Christof Rass Richard Greil Alexander Egle 《European journal of haematology》2019,102(5):437-441
Acute myeloid leukemia (AML) is a disease of the elderly population and survival remains poor after failure of hypomethylating agents (HMA). The BCL‐2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML. In this case series, patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA were treated with venetoclax within a named patient program at our tertiary cancer center in Salzburg, Austria. Between April 2017 and September 2018, seven patients with sAML received venetoclax therapy. Two out of seven patients achieved a complete remission upon venetoclax initiation with a PFS of 505 days and 352 days and another patient achieved complete peripheral blood blast clearing within nine days after start of venetoclax. Among the venetoclax responders, primary refractory disease to prior HMA therapy was documented, 2 patients harbored IDH1/IDH2 mutations and one patient had an antecedent myeloproliferative neoplasm. High BCL‐2 and/or BIM expression in myeloblasts was found in venetoclax responders and response was significantly associated with overall survival (responders: 364 days versus non‐responders: 24 days, P = 0.018). Venetoclax monotherapy is safe and is able to induce durable responses in elderly patients with secondary AML after treatment failure with HMA. 相似文献
2.
Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma
3.
Florian Lemaitre Nolwen Lorcy Camille Tron Lonard Golbin Antoine Petitcollin Marie‐Clmence Verdier Ccile Vigneau Eric Bellissant 《Fundamental & clinical pharmacology》2019,33(3):347-354
In liver transplantation, tacrolimus trough concentrations (Cmin) above 20 ng/mL during the first days led to worse outcome at 1 year but data in the kidney transplant (KT) era are scarce. The aim of this study was to evaluate the impact of tacrolimus overexposure during the first week post‐transplantation on the kidney function (KF) of KT recipients. In this retrospective study, 105 KT recipients were attributed to overexposure group (OG) or normal group according to their Cmin during the first week of treatment. KF was evaluated by comparing the rate of delayed graft function (DGF) and by collecting plasma creatinine from day 1, 2, 3, 4, 5, 6, 7, 14, 21, 28 and at 1 year. Risk factors for developing DGF were also investigated using a multivariate model. DGF was more frequent in OG (43% of patients; P = 0.027) which has higher plasma creatinine on day 7, 14, and 21. OG patients were older with more extended criteria donor's grafts. In the multivariate analysis, only cold ischemia time (CIT) remained associated with DGF (OR = 1.003), while TAC overexposure did not reach significance (P = 0.06; OR = 3.9). In this study, we confirmed the predominant role of CIT as a risk factor for the onset of DGF in kidney transplantation. 43% of KT recipients were overexposed with more DGF, especially older patients. 相似文献
4.
Stefan Scholz Florian Koerber Kinga Meszaros Rosa Maya Fassbender Bernhard Ultsch Robert R. Welte Wolfgang Greiner 《Vaccine》2019,37(12):1692-1701
Introduction
Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and young children. The most common serogroup causing IMD in Germany is the serogroup type B Neisseria meningitidis (MenB). The aim of the present study is to estimate the economic burden of MenB-related IMD in Germany.Method
A bottom-up, model-based costing approach has been used to calculate the diagnose- and age-specific yearly lifetime costs of a hypothetical cohort of MenB-related IMD cases. Direct costs contain the treatment cost for the acute phase of the disease, long-term sequelae, costs for rehabilitation, and public health response. Indirect costs are calculated for the human-capital approach and the friction-cost approach considering productivity losses of patients or parents for the acute phase and long-term sequelae. Publicly available databases from the Federal Statistical Office, the SOEP panel data set, literature, and expert opinion were used as data sources. All future costs beyond the reference year of 2015 were discounted at 3%.Results
The total costs for the hypothetical cohort (343 patients) from a societal perspective are €19.6 million (€57,100/IMD case) using the friction-cost approach and €58.8 million (€171,000/IMD case) using the human-capital approach. Direct costs amount to €18.6 million or €54,300 €/case. Sequelae are responsible for 81% of the direct costs/case.Discussion
The elevated costs/MenB-related IMD case reflect the severity of the disease. The total costs are sensitive to the productivity-loss estimation approach applied. MenB is an uncommon but severe disease; The costs/case reflect the severity of the disease and is within the same magnitude as for human papilloma virus infections. The available literature on sequelae is due to the uncommonness limited and heterogeneous. 相似文献5.
6.
Qingyang Xiao Yitian Zhou Stefan Winter Florian Büttner Elke Schaeffeler Matthias Schwab Volker M. Lauschke 《International journal of cancer. Journal international du cancer》2020,146(9):2475-2487
Multidrug resistance due to facilitated drug efflux mediated by ATP-binding cassette (ABC) transporters is a main cause for failure of cancer therapy. Genetic polymorphisms in ABC genes affect the disposition of chemotherapeutics and constitute important biomarkers for therapeutic response and toxicity. Here we correlated germline variability in ABC transporters with disease-specific survival (DSS) in 960 breast cancer (BRCA), 314 clear cell renal cell carcinoma and 325 hepatocellular carcinoma patients. We find that variant burden in ABCC1 is a strong predictor of DSS in BRCA patients, whereas candidate polymorphisms are not associated with DSS. This association is highly drug-specific for subgroups treated with the MRP1 substrates cyclophosphamide (log-rank p = 0.0011) and doxorubicin (log-rank p = 0.0088) independent of age and tumor stage, whereas no association was found in individuals treated with tamoxifen (log-rank p = 0.13). Structural mapping of significant variants revealed multiple variants at residues involved in protein stability, cofactor stabilization or substrate binding. Our results demonstrate that BRCA patients with high variant burden in ABCC1 are less prone to respond appropriately to pharmacological therapy with MRP1 substrates, thus incentivizing the consideration of genomic germline data for precision cancer medicine. 相似文献
7.
8.
Javier Jarazo PhD Kyriaki Barmpa MSc Jennifer Modamio PhD Cláudia Saraiva PhD Sònia Sabaté-Soler MSc Isabel Rosety MSc Anne Griesbeck PhD Florian Skwirblies BSc Gaia Zaffaroni PhD Lisa M. Smits PhD Jihui Su BSc Jonathan Arias-Fuenzalida PhD Jonas Walter PhD Gemma Gomez-Giro PhD Anna S. Monzel PhD Xiaobing Qing PhD Armelle Vitali MSc Gerald Cruciani MSc Ibrahim Boussaad PhD Francesco Brunelli PhD Christian Jäger PhD Aleksandar Rakovic PhD Wen Li PhD Lin Yuan PhD Emanuel Berger PhD Giuseppe Arena PhD Silvia Bolognin PhD Ronny Schmidt PhD Christoph Schröder PhD Paul M.A. Antony PhD Christine Klein MD Rejko Krüger MD Philip Seibler PhD Jens C. Schwamborn PhD 《Movement disorders》2022,37(1):80-94
9.
Johanna C. Bendell Tamara Sauri Antonio Cubillo Gracián Rafael Alvarez Carlos López-López Pilar García-Alfonso Maen Hussein Maria-Luisa Limon Miron Andrés Cervantes Clara Montagut Cristina Santos Vivas Alberto Bessudo Patricia Plezia Veerle Moons Johannes Andel Jaafar Bennouna Andre van der Westhuizen Leslie Samuel Simona Rossomanno Christophe Boetsch Angelika Lahr Izolda Franjkovic Florian Heil Katharina Lechner Oliver Krieter Herbert Hurwitz for the McCAVE Study Group 《The oncologist》2020,25(3):e451-e459
10.